STK11 and non-small cell lung carcinoma: Therefore, this review aims to highlight the current research of STK11 mutations in late stage NSCLC, the considerations for its potential implementation in routine clinical care, and finally the current limitations of using the STK11 mutational status in decision making of the global therapeutic strategy in thoracic oncology.